Bristi Basu
A5017721654- Ovarian cancer diagnosis and treatment
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- PI3K/AKT/mTOR signaling in cancer
- PARP inhibition in cancer therapy
- Gastric Cancer Management and Outcomes
- Histone Deacetylase Inhibitors Research
- Lung Cancer Treatments and Mutations
- Growth Hormone and Insulin-like Growth Factors
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Cancer, Lipids, and Metabolism
- Angiogenesis and VEGF in Cancer
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Advanced NMR Techniques and Applications
- Cancer Treatment and Pharmacology
- Folate and B Vitamins Research
- Advanced MRI Techniques and Applications
- Cancer Mechanisms and Therapy
Cambridge University Hospitals NHS Foundation Trust
2015-2024
University of Cambridge
2015-2024
Cancer Research UK Cambridge Center
2011-2024
Addenbrooke's Hospital
2010-2023
Cancer Research UK
2010-2023
Clinica Universidad de Navarra
2022
National Health Service
2022
Nil Ratan Sircar Medical College and Hospital
2022
Hutchison/MRC Research Centre
2015-2020
Barts Health NHS Trust
2016
Significance Patients with microsatellite stable (MSS) pancreatic (PDA) or colorectal cancer (CRC) do not respond to immunotherapy inhibitors of T cell checkpoints. A possible explanation is suggested by finding that cells in these tumors are coated the chemokine, CXCL12, and stimulation CXCR4, CXCL12 receptor on immune cells, suppresses directed migration mediated other chemokine receptors cells. We assessed relevance findings treating patients for seven days continuous infusion...
Our purpose is to investigate the feasibility of imaging tumor metabolism in breast cancer patients using 13 C magnetic resonance spectroscopic (MRSI) hyperpolarized label exchange between injected [1- C]pyruvate and endogenous lactate pool. Treatment-naïve were recruited: four triple-negative grade 3 cancers; two invasive ductal carcinomas that estrogen progesterone receptor-positive (ER/PR+) HER2/neu-negative (HER2−), one 2 3; ER/PR+ HER2− lobular carcinoma (ILC). Dynamic MRSI was...
Hyperpolarized 13C Magnetic Resonance Imaging (13C-MRI) provides a highly sensitive tool to probe tissue metabolism in vivo and has recently been translated into clinical studies. We report the cerebral of intravenously injected hyperpolarized [1–13C]pyruvate brain healthy human volunteers for first time. Dynamic acquisition images demonstrated 13C-labeling both lactate bicarbonate, catalyzed by cytosolic dehydrogenase mitochondrial pyruvate respectively. This demonstrates that enzymes can...
Abstract Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-acid (ATRA) reprograms stroma to suppress ductal adenocarcinoma (PDAC) growth. Here, in a phase Ib, dose escalation and expansion, trial for patients advanced, unresectable PDAC (n = 27), ATRA is re-purposed as stromal-targeting agent combination gemcitabine-nab-paclitaxel chemotherapy using two-step adaptive continual re-assessment method design. The maximum tolerated (MTD) recommended 2...
Pancreatic cancer is the tenth most common in UK; however, outcomes are poor, part due to late diagnosis. We aimed identify symptoms and other clinical sociodemographic factors associated with pancreatic diagnosis diagnostic intervals.We did this prospective cohort study at seven hospitals two regions England. recruited participants aged 40 years or older who were referred for suspicion of cancer. Data collected by use a patient questionnaire primary care hospital records. Descriptive...
Abstract Purpose: Transcription factor C/EBP-α (CCAAT/enhancer-binding protein alpha) acts as a master regulator of hepatic and myeloid functions multiple oncogenic processes. MTL-CEBPA is first-in-class small activating RNA oligonucleotide drug that upregulates C/EBP-α. Patients Methods: We conducted phase I, open-label, dose-escalation trial in adults with advanced hepatocellular carcinoma (HCC) cirrhosis, or resulting from nonalcoholic steatohepatitis liver metastases. received...
AZD2014 is a novel, oral, m-TORC 1/2 inhibitor that has shown in vitro and vivo efficacy across range of preclinical human cancer models.A rolling six-dose escalation was performed to define an MTD (part A), at further cohort patients treated characterize toxicities perform pre- posttreatment biopsies B). administered orally twice day continuously. Flow cytometry, ELISA, immunohistochemistry were used quantify pharmacodynamic biomarkers. Pharmacokinetic analysis carried out by mass...
The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase inhibitors has been shown to be effective pre-clinical models of pancreatic cancer, combination with gemcitabine. A multi-centre, non-randomised Bayesian adaptive design study MK-0752, administered per os weekly, gemcitabine intravenously on days 1, 8 and 15 (28 day cycle) at 800 or 1000 mg m-2, was performed determine the safety treatment recommended phase 2 dose (RP2D). Secondary tertiary objectives...
Abstract Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in BRCA1 BRCA2 (BRCA1/2)–deficient BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient dose- escalation design to assess two schedules of capivasertib (AKT inhibitor) with olaparib (PARP 64 patients advanced solid Dose expansions enrolled germline BRCA1/2-mutant tumors, or BRCA1/2 wild-type cancers harboring somatic DNA damage...
Abstract Purpose: To evaluate the mechanisms of how therapeutic upregulation transcription factor, CCAAT/enhancer-binding protein alpha (C/EBPα), prevents tumor progression in patients with advanced hepatocellular carcinoma (HCC) and different mouse models. Experimental Design: We conducted a phase I trial 36 HCC (NCT02716012) who received sorafenib as part their standard care, were given C/EBPα small activating RNA (saRNA; MTL-CEBPA) either neoadjuvant or adjuvant treatment. In preclinical...
94 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) mismatch repair (MMR) deficient colorectal cancer, both as first-line and after progression following fluoropyrimidine, oxaliplatin, irinotecan. The combination lenvatinib, a multiple receptor tyrosine kinase inhibitor, showed synergistic antitumor activity in preclinical models. LEAP-005 (NCT03797326) evaluating...
2580 Background: BMN 673 is the most potent and specific inhibitor of PARP1/2 in clinical development (IC 50 <1nM). In tumors genetically dependent on DNA repair by homologous recombination PARP inhibition induces synthetic lethality. Methods: Pharmacokinetics (PK), pharmacodynamics (PD), safety anti-tumor activity were evaluated a 2-stage dose-escalation study with 3-6 patients (pts)/dose level. dose escalation (Stage 1) cycle 1 was 6 wks, drug taken days 8-35, for PK PD assays, followed...
Abstract Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing cancer. This randomized phase II trial compared guadecitabine, a second-generation HMA, and (G+C) against second-line chemotherapy women measurable or detectable platinum-resistant Patients Methods: received either G+C (guadecitabine 30 mg/m2 s.c. once-daily for 5 days carboplatin) treatment of choice (TC; topotecan,...
Abstract Background Liquid biopsy based on cell-free DNA circulating in plasma has shown solid results as a non-invasive biomarker. In the present study we evaluated utility of free (cfDNA) and sub-type tumor (ctDNA) hepatocellular cancer (HCC) patients to assess therapy response clinical outcome. Methods A cohort 13 recruited context SORAMIC trial with unresectable, advanced HCC different etiological clinicopathological characteristics was included this exploratory study. Plasma samples...
The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures been interrupted delayed because COVID-19 pandemic.An international survey impact on clinical practice trials from March 2020 June 2020, as first phase a multicentre, international, observational project. focus was hepatocellular carcinoma intrahepatic...
Abstract All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers potential enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with primary objective exploring safety and tolerability MOv18 chimeric first-in-class IgE antibody, in patients tumours expressing relevant antigen, folate receptor-alpha. The incorporated skin prick basophil activation tests (BAT) to select at...
DNA binding 4-(1-methyl-1H-pyrrol-3-yl)benzenamine (MPB) building blocks have been developed that span two base pairs with a strong preference for GC-rich DNA. They conjugated to pyrrolo[2,1-c][1,4]benzodiazepine (PBD) molecule produce C8-linked PBD–MPB hybrids can stabilize by up 13-fold compared AT-rich Some subpicomolar IC50 values in human tumor cell lines and primary chronic lymphocytic leukemia cells, while being 6 orders less cytotoxic the non-tumor line WI38, suggesting key sequences...
Purpose To compare hyperpolarized carbon 13 (13C) MRI with dynamic contrast material–enhanced (DCE) in the detection of early treatment response breast cancer. Materials and Methods In this institutional review board–approved prospective study, a woman triple-negative cancer (age, 49 years) underwent 13C after injection [1–carbon {13C}]-pyruvate DCE at 3 T baseline one cycle neoadjuvant therapy. The 13C-labeled lactate-to-pyruvate ratio derived from pharmacokinetic parameters transfer...
Chromosomal instability is a major challenge to patient stratification and targeted drug development for high-grade serous ovarian carcinoma (HGSOC). Here we show that somatic copy number alterations (SCNAs) in frequently amplified HGSOC cancer genes significantly correlate with gene expression methylation status. We identify five prevalent clonal driver SCNAs (chromosomal amplifications encompassing MYC, PIK3CA, CCNE1, KRAS TERT) from multi-regional data reason their strong selection should...